Vaccine News and Research

Latest Vaccine News and Research

Researchers study molecular mechanisms in early stages of IPN virus infection

Infectious pancreatic necrosis is a serious disease that leads to enormous losses in the salmon industry each year. The virus that causes the disease, IPN, is very prevalent in farmed salmon and trout in Norway. The virus attacks a wide diversity of hosts and has been found to occur in many different fish species, in addition to shellfish and molluscs.

30 Dec 2010

Centocor Ortho Biotech files REMICADE sBLA for ulcerative colitis in pediatric patients

Centocor Ortho Biotech Inc. announced today that it has filed a supplemental Biologics License Application (sBLA) with the U.S. Food and Drug Administration (FDA) requesting the approval of REMICADE® (infliximab) for the treatment of moderately to severely active ulcerative colitis (UC) in pediatric patients who have had an inadequate response to conventional therapy.

29 Dec 2010

CEL-SCI initiates Multikine Phase III trail for head and neck cancer

CEL-SCI Corporation announced today that it has commenced its Phase III clinical trial for Multikine®, the Company's flagship immunotherapy. CEL-SCI has now completed all of the manufacturing and regulatory requirements to begin enrollment of the study.

29 Dec 2010

Molecular interaction between structural HCV protein and protein critical to viral replication identified

Scientists from the Florida campus of The Scripps Research Institute have identified a molecular interaction between a structural hepatitis C virus protein (HCV) and a protein critical to viral replication. This new finding strongly suggests a novel method of inhibiting the production of the virus and a potential new therapeutic target for hepatitis C drug development.

29 Dec 2010

Sinovac's inactivated EV71 vaccine clinical trial against HFMD receives Chinese SFDA approval

Sinovac Biotech Ltd., a leading provider of biopharmaceutical products in China, announced today that it received approval from the China State Food and Drug Administration (SFDA) to commence clinical trials for its proprietary inactivated EV71 vaccine against Hand, Foot and Mouth Disease (HFMD).

28 Dec 2010

Intellect obtains pharmacokinetic data from OX1 Phase 1b trial for Alzheimer's disease

Intellect Neurosciences, Inc., a biopharmaceutical company with an internal preclinical and clinical-stage pipeline and multiple licenses with major pharmaceutical companies covering products in late-stage clinical trials, announced that it has obtained a draft pharmacokinetic report from its completed Phase 1b trial for its lead Alzheimer's candidate, OX1. The Company previously reported on the safety aspects of the trial, which demonstrated that OX1 is safe and well tolerated at all dose levels tested.

28 Dec 2010

Emergent initiates AV7909 Phase I trail for Anthrax vaccine

Emergent BioSolutions today announced the initiation of a Phase I clinical trial for NuThraxTM, also known as AV7909, with the dosing of the first subject.

27 Dec 2010

Flu infection rates double in a week

Figures reveal that the rates of flu infection in the UK have more than doubled in the last week. Number of cases has risen to 87.1 per 100,000 people, from 32.8 in the previous week, according to the Royal College of GPs. Reports also reveal that school-age children from England and Wales are particularly affected. Ages five to 14 are highest affected followed by those under four, then people aged 15 to 44. Considering all age groups rates almost tripled in the South in one week, from 36 per 100,000 to 93.4. In the North, the rate was 55.5, up from 15.7, and was 94.9 in the central England region, up from 37.9.

27 Dec 2010

AMPK activates autophagy by activating ATG1 enzyme

Researchers at the Salk Institute for Biological Studies have discovered how AMPK, a metabolic master switch that springs into gear when cells run low on energy, revs up a cellular recycling program to free up essential molecular building blocks in times of need.

24 Dec 2010

Financial Times examines how Brazil's state-run drug sector is engaging in partnerships at home, abroad

"Dilma Rousseff had barely been confirmed as Brazil's new president in November when she made her first foreign visit, to Mozambique," which "included a symbolic stop-off at a pharmaceutical factory that is under construction in preparation for opening in 2014. … The plant will produce a range of medicines for one of its leading lusophone - Portuguese-speaking - African partners, marking the resurgent power and growing reach of its sponsor, Brazil's own state-led drug sector," the Financial Times writes in an article that examines the partnerships Brazil is establishing at home and abroad.

24 Dec 2010

Silencing of specific genes of germinal cell lines reduces brain tumors

Scientists at IRB Barcelona have discovered that some brain tumours in larvae of the fruit fly Drosophila melanogaster use the genetic programme of germline cells to grow. The removal of some of these genes leads to healthy brains. This finding demonstrates that these genes are crucial for tumour development. The study, headed by ICREA researcher Cayetano Gonz-lez, is published today in the prestigious journal Science.

24 Dec 2010

BROMG doctor calls for votes to win $25,000 Pepsi Refresh Grant to pay for more flu vaccine

Dr. M. George of the Birmingham Royal Oak Medical Group (BROMG) is well known for providing free flu shots for the past thirteen years to more than 28,000 people in his community at a cost of $300,000 to his clinic. He also provides free Doctor visits for the unemployed and the uninsured. Now, Doc George, as he is known, is asking for help to win a Pepsi Refresh Grant of $25,000 to pay for more flu vaccine.

23 Dec 2010

Scientist discovers molecular switch controlling synthesis of ribosomes

A scientist from the Florida campus of The Scripps Research Institute has discovered a molecular switch that controls the synthesis of ribosomes. Ribosomes are the large machineries inside all living cells that produce proteins, the basic working units of any cell. These new findings offer a novel target for potential treatments for a range of diseases, including cancer.

23 Dec 2010

Immunization with VLP vaccine results in functional, protective immune responses against RSV

Novavax, and scientists at the University of Massachusetts Medical School, led by Dr. Trudy Morrison, published in the January 2011 issue of The Journal of Virology, a report indicating that a novel virus-like particle vaccine candidate against respiratory syncytial virus (RSV) protects mice from a live virus challenge.

23 Dec 2010

Pfizer seeks FDA and EMA approval for expanded use of Prevnar 13 for pneumococcal disease

Pfizer Inc today announced that it has submitted supplemental applications to both the United States Food and Drug Administration (FDA) and the European Medicines Agency (EMA) to expand the use of Prevnar 13® (Pneumococcal 13-valent Conjugate Vaccine [Diphtheria CRM197 Protein]) to adults 50 years of age and older for the prevention of pneumococcal disease caused by the 13 serotypes contained in the vaccine.

23 Dec 2010

Medicago completes first part of H5N1 vaccine Phase II trial

Medicago, a biotechnology company focused on developing highly effective and affordable vaccines based on proprietary manufacturing technologies and Virus-Like Particles, today announced that the last dose of vaccine has been administered completing the first part of the Company's Phase II human clinical trial with its H5N1 Avian Influenza vaccine.

23 Dec 2010

Merck announces FDA approval for GARDASIL against HPV-related anal cancer

Merck, known as MSD outside the United States and Canada, announced today that the U.S. Food and Drug Administration (FDA) has approved GARDASIL® [Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) Vaccine, Recombinant] for the prevention of anal cancer caused by human papillomavirus (HPV) types 16 and 18 and for the prevention of anal intraepithelial neoplasia (AIN) grades 1, 2 and 3 (anal dysplasias and precancerous lesions) caused by HPV types 6, 11, 16 and 18, in males and females 9 through 26 years of age.

23 Dec 2010

Combination of antigen and wax nanoparticles improves immunogenicity

Particle Sciences, a leading pharmaceutical CRO has formulated a series of wax nanoparticles that, when coupled with an antigen, enhanced its immunogenicity, increasing both systemic and the mucosal immune response.

23 Dec 2010

FDA approves Gardasil for prevention of anal cancer

The U.S. Food and Drug Administration today approved the vaccine Gardasil for the prevention of anal cancer and associated precancerous lesions due to human papillomavirus (HPV) types 6, 11, 16, and 18 in people ages 9 through 26 years.

23 Dec 2010

New online tool helps scientists to find gene promoters

Researchers at The Wistar Institute announce the release of an online tool that will help scientists find "gene promoters"—regions along a DNA strand that tell a cell's transcription machinery where to start reading in order to create a particular protein.

22 Dec 2010

Vaccine News and Research

Latest Vaccine News and Research

Researchers study molecular mechanisms in early stages of IPN virus infection

Centocor Ortho Biotech files REMICADE sBLA for ulcerative colitis in pediatric patients

CEL-SCI initiates Multikine Phase III trail for head and neck cancer

Molecular interaction between structural HCV protein and protein critical to viral replication identified

Sinovac's inactivated EV71 vaccine clinical trial against HFMD receives Chinese SFDA approval

Intellect obtains pharmacokinetic data from OX1 Phase 1b trial for Alzheimer's disease

Emergent initiates AV7909 Phase I trail for Anthrax vaccine

Flu infection rates double in a week

AMPK activates autophagy by activating ATG1 enzyme

Financial Times examines how Brazil's state-run drug sector is engaging in partnerships at home, abroad

Silencing of specific genes of germinal cell lines reduces brain tumors

BROMG doctor calls for votes to win $25,000 Pepsi Refresh Grant to pay for more flu vaccine

Scientist discovers molecular switch controlling synthesis of ribosomes

Immunization with VLP vaccine results in functional, protective immune responses against RSV

Pfizer seeks FDA and EMA approval for expanded use of Prevnar 13 for pneumococcal disease

Medicago completes first part of H5N1 vaccine Phase II trial

Merck announces FDA approval for GARDASIL against HPV-related anal cancer

Combination of antigen and wax nanoparticles improves immunogenicity

FDA approves Gardasil for prevention of anal cancer

New online tool helps scientists to find gene promoters

Achieving and maintaining ISO 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Vaccine News and Research

Latest Vaccine News and Research

Achieving and maintaining ISO 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Newsletters you may be interested in